The Potential Of Cassava Sciences Inc. (SAVA) Is Not A Fantasy

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Cassava Sciences Inc. (SAVA) grew significantly in the past year. A Phase II study of a new Alzheimer’s treatment received a positive response from investors. Should Cassava Sciences see an increase in costs if the Phase III trials succeed and the drug is commercialized?

Phase III trials on similar, a treatment for moderate to mild Alzheimer’s disease, start later this year at Cassava Science. A previous phase of the trials has demonstrated that the candidate’s safety is demonstrated and can improve spatial working memory compared to a placebo.

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


A breakthrough in Alzheimer’s disease treatment will likely arrive with the introduction of similar. Healthcare firms have been waiting for this breakthrough for more than a decade now. In the past six months, Cassava Sciences shares’ price has increased by more than 1300%. Many have asked in the past: Is the company capable of continuing this growth if new trials prove successful?

Several biotech companies are in the third phase of clinical trials for drugs treating Alzheimer’s disease. Historically, it has been observed that about half the candidates pass the first stage of the procedure successfully. It is expected that 15-20 new competing drugs would appear in the next few years.

A similar drug will probably be in the mix. If it and its competitors do about and this one, they can expect to account for 6 – 7 % of the market. The Alzheimer’s disease market may reach $14.5 billion in 2027, according to some estimates. Hence, Cassaca Sciences could expect to make around $ 800 – $900 million in revenue from 2027 to 2035 with a share of 6 – 7%.

Cassava Sciences Inc (NASDAQ: SAVA) shares are 560.12% higher in the year-to-date period and have moved up 3.71% or $1.61 higher in the last trading session. Still, the stock’s trailing year-to-date performance stands nearly 645.36% higher. The stock is up 560.12% on a year-to-date basis, while it has gained 501.07% over the trailing 3-month period. Based on week performance, it’s -10.07% over the past week and -29.02% over the past month.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Is Stereotaxis Inc. (STXS) a Keeper?

Stereotaxis Inc. (AMEX:STXS) went up by 0.36% from its latest closing price compared to the recent 1-year high of $8.57. The company’s stock price has

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.